Login to Your Account

Prior to Commercialization, Pharmacyclics Brings in $270M

By Catherine Shaffer
Staff Writer

Friday, March 8, 2013
Following receipt of the FDA's new Breakthrough Therapy Designation for its investigational cancer compound, ibrutinib, Pharmacyclics Inc., of Sunnyvale, Calif., is gearing up for commercial launch by pricing its public offering of 2.2 million shares of common stock at $94.20 per share, for a total raise of $207.2 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription